4D Molecular Therapeutics Inc
FDMT
Company Profile
Business description
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).
Contact
5858 Horton Street
Suite 455
EmeryvilleCA94608
USAT: +1 510 505-2680
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
196
Stocks News & Analysis
stocks
ASX healthcare giant rallies despite a fall in profits
Easing investor concerns and signalling a return to growth.
stocks
Weekly earnings wrap: BHP, CSL, NAB and more
Materials, banking, healthcare and retail heavyweights reveal diverging outlooks.
stocks
Chart of the Week: Our top dividend stock picks on the ASX
Highlighting key income opportunities on the ASX.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,255.20 | 20.50 | 0.22% |
| CAC 40 | 8,501.91 | 7.45 | -0.09% |
| DAX 40 | 26,091.33 | 37.03 | -0.14% |
| Dow JONES (US) | 53,463.05 | 119.65 | 0.22% |
| FTSE 100 | 10,743.35 | 15.31 | 0.14% |
| HKSE | 25,495.07 | 23.92 | 0.09% |
| NASDAQ | 26,331.09 | 41.38 | 0.16% |
| Nikkei 225 | 65,326.42 | 2,134.30 | -3.16% |
| NZX 50 Index | 13,929.67 | 63.49 | 0.46% |
| S&P 500 | 7,707.98 | 16.22 | 0.21% |
| S&P/ASX 200 | 9,053.80 | 25.20 | 0.28% |
| SSE Composite Index | 3,894.42 | 95.88 | -2.40% |